NewBridge Pharmaceuticals is a regional specialty company established to bridge the access gap and partner with pharma & biotech companies to in-license and commercialize FDA or EMA/European approved innovative pharmaceutics, biologics, & other healthcare solutions in the Middle East and Africa region. The areas of Oncology, Immunology, Neuroscience, Gastrointestinal & Nutrition are NewBridge’s current strategic focus. The existing product portfolio was built to address unmet medical needs in the region & enabled the company not just to gain substantial presence, but also to help patients gain access to these much-needed innovations. NewBridge is driven by highly experienced leadership in the biopharmaceutical industry regionally & globally, as well as talented motivated teams with a proven track record of regional achievements, which collectively has allowed NewBridge to establish itself as a strategic & successful pharmaceutical partner of choice in the MENA Region. NewBridge offers flexible partnership opportunities & best practices in the areas of commercial, regulatory, and medical affairs striving for quality performance & high standards of compliance that pharmaceutical companies look for in a partner to serve as an extension of their practices & values in local markets. NewBridge is well backed by strong institutional & corporate investors who provide us with the extensive life science network & diverse investment expertise needed to achieve our vision & build a platform of successful alliances in the region, and create value in an innovative business approach. This integrated strategy of regional expertise & strong global business network position NewBridge uniquely as an institutional one-stop-solution for our partners in its offering & as a preferred partner-of-choice for the biopharmaceutical & other healthcare companies seeking multi-country access in Middle East and Africa with its growing economies, yet complex regulations & access hurdles.
View Top Employees from NewBridge PharmaceuticalsWebsite | https://nbpharma.com |
Revenue | $20.7 million |
Funding | $12 million |
Employees | 232 (200 on RocketReach) |
Founded | 2010 |
Address | 500618 Po Box, Dubai, AE |
Phone | (415) 591-5400 |
Fax | +971 4 429 8677 |
Technologies |
JavaScript,
HTML,
PHP
+21 more
(view full list)
|
Industry | Biotechnology, Pharmaceutical Manufacturing, Manufacturing General, Manufacturing, Science and Engineering, Pharmaceuticals, Medical Device, Health Care, Pharmaceutical |
Web Rank | 4 Million |
Keywords | Pharmaceutical Solutions, Healthcare Solution, Biotechnology, Specialty Pharmaceutical |
Competitors | Chiesi USA, Inc., QOL Medical LLC, Therapeutic Products Inc, URL Pharma, Inc., World Med LLC |
SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 42421 Companies, NAICS Code 42 Companies, NAICS Code 424 Companies, NAICS Code 325 Companies, NAICS Code 4242 Companies, NAICS Code 32 Companies |
Looking for a particular NewBridge Pharmaceuticals employee's phone or email?
The NewBridge Pharmaceuticals annual revenue was $20.7 million in 2024.
Hisham Sayed is the Executive Vice President of NewBridge Pharmaceuticals.
200 people are employed at NewBridge Pharmaceuticals.
The NAICS codes for NewBridge Pharmaceuticals are [42421, 42, 424, 325, 4242, 32].
The SIC codes for NewBridge Pharmaceuticals are [28, 283, 80].